dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | van Weelden, Willem Jan |
dc.contributor.author | Lalisang, Roy I. |
dc.contributor.author | van Beekhuizen, Heleen J. |
dc.contributor.author | Trum, Hans |
dc.contributor.author | Cabrera Diaz, Silvia |
dc.contributor.author | Bulten, Johan |
dc.contributor.author | Lindemann, Kristina |
dc.date.accessioned | 2022-01-13T17:48:27Z |
dc.date.available | 2022-01-13T17:48:27Z |
dc.date.issued | 2021-10-01 |
dc.identifier.citation | van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, et al. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. Am J Obstet Gynecol. 2021 Oct 1;225(4):407.e1-407.e16. |
dc.identifier.issn | 0002-9378 |
dc.identifier.uri | https://hdl.handle.net/11351/6796 |
dc.description | Inhibidors de l'aromatasa; Teràpia amb progestina |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | American Journal of Obstetrics & Gynecology;225(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Endometri - Càncer - Hormonoteràpia |
dc.subject | Càncer - Recaiguda |
dc.subject.mesh | Endometrial Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Antineoplastic Agents, Hormonal |
dc.subject.mesh | /therapeutic use |
dc.title | Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ajog.2021.05.007 |
dc.subject.decs | neoplasias endometriales |
dc.subject.decs | /terapia |
dc.subject.decs | antineoplásicos hormonales |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.ajog.2021.05.007 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [van Weelden WJ] Department of Obstetrics and Gynaecology, Radboud Institute of Health Sciences, Radboud university medical center, Nijmegen, the Netherlands. [Lalisang RI] Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands. GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands. [Bulten J] Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. [Lindemann K] Division of Medicine, Department of Gynecological Oncology, Oslo University Hospital, Oslo, Norway. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. [van Beekhuizen HJ] Department of Gynecologic Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands. [Trum H] Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, the Netherlands. [Cabrera S] Unitat d’Oncologia Ginecològica, Departament d'Obstetrícia i Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34019887 |
dc.identifier.wos | 000720311600011 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |